Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1975 2
1976 1
1977 3
1978 1
1979 1
1980 2
1981 4
1982 1
1983 4
1984 3
1985 6
1986 4
1987 7
1988 4
1989 14
1990 10
1991 18
1992 15
1993 14
1994 21
1995 27
1996 17
1997 25
1998 25
1999 27
2000 43
2001 31
2002 41
2003 45
2004 44
2005 29
2006 46
2007 35
2008 36
2009 41
2010 53
2011 59
2012 61
2013 47
2014 63
2015 80
2016 83
2017 74
2018 64
2019 61
2020 64
2021 66
2022 77
2023 81
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

1,434 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Chronic Leukemia"
Page 1
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E, Kantarjian H. Jabbour E, et al. Am J Hematol. 2022 Sep;97(9):1236-1256. doi: 10.1002/ajh.26642. Epub 2022 Jul 6. Am J Hematol. 2022. PMID: 35751859 Free article.
DISEASE OVERVIEW: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. DIAGNOSIS: CML is characterized by a balance …
DISEASE OVERVIEW: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 a …
Chronic lymphocytic leukaemia.
Hallek M, Shanafelt TD, Eichhorst B. Hallek M, et al. Lancet. 2018 Apr 14;391(10129):1524-1537. doi: 10.1016/S0140-6736(18)30422-7. Epub 2018 Feb 21. Lancet. 2018. PMID: 29477250 Review.
Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. ...In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and high …
Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagno …
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S. Cross NCP, et al. Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4. Leukemia. 2023. PMID: 37794101 Free PMC article. Review.
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of possible reasons for resista …
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagno …
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.
Vetrie D, Helgason GV, Copland M. Vetrie D, et al. Nat Rev Cancer. 2020 Mar;20(3):158-173. doi: 10.1038/s41568-019-0230-9. Epub 2020 Jan 6. Nat Rev Cancer. 2020. PMID: 31907378 Free article. Review.
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell field. ...Furthermore, LSCs from both AML and CML can be refractory to standard-of-c …
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML …
Mutations driving CLL and their evolution in progression and relapse.
Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ. Landau DA, et al. Nature. 2015 Oct 22;526(7574):525-30. doi: 10.1038/nature15395. Epub 2015 Oct 14. Nature. 2015. PMID: 26466571 Free PMC article.
Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and therapy are central questions in cancer biology. Here we identify 44 recurrently mutated genes and 11 recurrent somatic copy number variations through whole-exome sequen …
Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and therapy are central questions in cancer bio …
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Siddiqi T, et al. Blood. 2022 Mar 24;139(12):1794-1806. doi: 10.1182/blood.2021011895. Blood. 2022. PMID: 34699592 Free PMC article. Clinical Trial.
Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). ...
Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly diagnosed and relapsed/refractory chronic l …
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Winters AC, et al. Transplant Cell Ther. 2022 Oct;28(10):694.e1-694.e9. doi: 10.1016/j.jtct.2022.07.022. Epub 2022 Jul 25. Transplant Cell Ther. 2022. PMID: 35902048 Free article.
Allogeneic hematopoietic stem cell transplantation (SCT) after a patient with acute myeloid leukemia (AML) achieves a remission from intensive chemotherapy (IC) is given with curative intent. ...Relapse, transplantation-related mortality, incidence of acute and chronic …
Allogeneic hematopoietic stem cell transplantation (SCT) after a patient with acute myeloid leukemia (AML) achieves a remission from …
Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM, Padron E. Hunter AM, et al. Best Pract Res Clin Haematol. 2020 Sep;33(3):101195. doi: 10.1016/j.beha.2020.101195. Epub 2020 Jul 5. Best Pract Res Clin Haematol. 2020. PMID: 33038984 Review.
Formally recognized by the World Health Organization, this group includes the entities chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia, MDS/MPN with ring sideroblasts and thrombocytosis and MD …
Formally recognized by the World Health Organization, this group includes the entities chronic myelomonocytic leukemia, juveni …
Cytogenetics in the genomic era.
Granada I, Palomo L, Ruiz-Xivillé N, Mallo M, Solé F. Granada I, et al. Best Pract Res Clin Haematol. 2020 Sep;33(3):101196. doi: 10.1016/j.beha.2020.101196. Epub 2020 Jun 4. Best Pract Res Clin Haematol. 2020. PMID: 33038985 Review.
Chromosome banding analysis is mandatory for chronic myeloid leukaemia, neoplasms with eosinophilia, myelodysplastic syndromes and acute leukaemias. In contrast, in other myeloid neoplasms, chronic lymphocytic leukaemia, non-Hodgkin lymphoma and …
Chromosome banding analysis is mandatory for chronic myeloid leukaemia, neoplasms with eosinophilia, myelodysplastic syndromes …
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.
Holtan SG, Savid-Frontera C, Walton K, Eaton AA, Demorest C, Hoeschen A, Zhang L, Reid K, Kurian T, Sayegh Z, Julia E, Maakaron J, Bachanova V, Jurdi NE, MacMillan ML, Weisdorf DJ, Felices M, Miller JS, Blazar BR, Davila ML, Betts BC. Holtan SG, et al. Clin Cancer Res. 2023 Mar 14;29(6):1114-1124. doi: 10.1158/1078-0432.CCR-22-2837. Clin Cancer Res. 2023. PMID: 36622700 Free PMC article.
PURPOSE: Acute and chronic GVHD remain major causes of transplant-related morbidity and mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). ...CD83 CAR T eliminate autoreactive CD83+ B cells isolated from patients with chronic GVHD, withou …
PURPOSE: Acute and chronic GVHD remain major causes of transplant-related morbidity and mortality (TRM) after allogeneic hematopoieti …
1,434 results